Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use
 
Yazarlar (5)
Prof. Dr. Dilek Akyüzlü Ankara Üniversitesi, Türkiye
Doç. Dr. Selin ÖZKAN KOTİLOĞLU Kırşehir Ahi Evran Üniversitesi, Türkiye
Dr. Öğr. Üyesi Şafak Yalçın Şahiner Kütahya Sağlık Bilimleri Üniversitesi, Türkiye
Ece Ağtaş Ertan
Ankara University, Türkiye
Prof. Dr. İnci İlhan Ankara Üniversitesi, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı EUROPEAN JOURNAL OF PHARMACOLOGY (Q1)
Dergi ISSN 0014-2999 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 04-2022
Cilt / Sayı / Sayfa 921 / 0 / 174862–0 DOI 10.1016/j.ejphar.2022.174862
Makale Linki http://dx.doi.org/10.1016/j.ejphar.2022.174862
Özet
In this case-control study (423 Turkish subjects), the functional pro-dynorphin (PDYN) 68-bp VNTR polymorphism was genotyped in opioid users receiving sublingual buprenorphine/naloxone treatment (SBNT; n = 129, 119 males and 10 females), in opioid users (OUD; n = 99, 90 males and 9 females), in alcohol users (AUD; n = 75, 75 males) and in controls (n = 120, 109 males and 11 females) to determine the effect of this polymorphism on different treatment responses, heroin or alcohol dependence as well as age onset of first use. The PDYN 68-bp alleles were determined based on the number of repeats and genotypes were classified as “short/short (SS)”, “short-long (SL)” and “long-long (LL)”. The intensity of craving, withdrawal, depression and anxiety were measured by the Substance Craving Scale (SCS), the Clinical Opiate Withdrawal Scale (COWS), the Beck Depression Inventory-II (BDI-II) and Beck …
Anahtar Kelimeler
Alcohol | Heroin | Buprenorphine | PDYN 68-bp VNTR | Age onset of first use